HPV介导的宫颈癌免疫改变整合分析
该研究利用癌症基因组图谱中130例HPV阳性与7例HPV阴性宫颈癌病例,比较基因表达与功能富集,分析免疫相关差异基因的拷贝数变异与突变,并以Kaplan-Meier法评估生存与复发差异。HPV阳性病例上调基因富集于免疫过程(P=1.05E-14~1.00E-05),鉴定出9个在至少10%HPV阳性病例中存在拷贝数变异、突变和/或表达改变的免疫基因;携带至少一个特征基因改变的患者总体复发更早,TFRC或MMP13表达改变可能提示部分患者生存不良(P=1.07E-07)。
要点
- HPV阳性宫颈癌上调基因富集于免疫过程(P=1.05E-14~1.00E-05)。
- 鉴定出9个在至少10%HPV阳性病例中存在拷贝数变异、突变和/或表达改变的免疫基因。
- 携带至少一个特征基因改变的患者总体复发更早,TFRC或MMP13表达改变可能提示部分患者生存不良(P=1.07E-07)。
核心结论
- 研究鉴定出一个与HPV阳性宫颈癌相关的免疫基因特征,该特征可能与宫颈癌早期复发相关。
研究设计与样本
- 基于癌症基因组图谱公共数据,比较130例HPV阳性与7例HPV阴性宫颈癌病例的基因表达水平与功能富集差异。
- 对差异表达的免疫基因进行拷贝数变异与基因突变分析。
- 采用Kaplan-Meier分析评估携带或不携带所鉴定免疫特征基因改变病例的生存与复发差异。
主要发现
- HPV阳性宫颈癌中上调基因富集于多种免疫过程基因本体条目(P=1.05E-14~1.00E-05)。
- 整合分析鉴定出9个免疫基因,在至少10%的HPV阳性宫颈癌病例中显示拷贝数变异、基因突变和/或基因表达改变。
- 基因组扩增可能导致部分HPV阳性病例中这些基因水平升高。
- 携带至少一个上述9个特征基因改变的患者总体复发更早。
- TFRC或MMP13表达改变可能提示部分宫颈癌患者生存不良(P=1.07E-07)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Human papillomavirus (HPV) infection is the primary cause of cervical cancer. HPV-mediated immune alterations are known to play crucial roles in determining viral persistence and host cell transformation. We sought to thoroughly understand HPV-directed immune alterations in cervical cancer by exploring publically available datasets. METHODS: 130 HPV positive and 7 HPV negative cervical cancer cases from The Cancer Genome Atlas were compared for differences in gene expression levels and functional enrichment. Analyses for copy number variation (CNV) and genetic mutation were conducted for differentially expressed immune genes. Kaplan-Meier analysis was performed to assess survival and relapse differences across cases with or without alterations of the identified immune signature genes. RESULTS: Genes up-regulated in HPV positive cervical cancer were enriched for various gene ontology terms of immune processes (P=1.05E-14~1.00E-05). Integrated analysis of the differentially expressed immune genes identified 9 genes that displayed either CNV, genetic mutation and/or gene expression changes in at least 10% of the cases of HPV positive cervical cancer. Genomic amplification may cause elevated levels of these genes in some HPV positive cases. Finally, patients with alterations in at least one of the nine signature genes overall had earlier relapse compared to those without any alterations. The altered expression of either TFRC or MMP13 may indicate poor survival for a subset of cervical cancer patients (P=1.07E-07). CONCLUSIONS: We identified a novel immune gene signature for HPV positive cervical cancer that is potentially associated with early relapse of cervical cancer.
引用
- Chen L, Luan S, Xia B, et al. Integrated analysis of HPV-mediated immune alterations in cervical cancer. Gynecol Oncol. 2018. PMID: 29572030. doi:10.1016/j.ygyno.2018.01.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。